(Q39741247)

English

Frequent PD-L1 expression in primary and metastatic penile squamous cell carcinoma: potential opportunities for immunotherapeutic approaches

scientific article published on 23 May 2016

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PMC publication ID

14 September 2017

Frequent PD-L1 expression in primary and metastatic penile squamous cell carcinoma: potential opportunities for immunotherapeutic approaches (English)

1 reference

Europe PubMed Central

PMC publication ID

14 September 2017

1 reference

based on heuristic

inferred from title

author name string

A M Udager

1

1 reference

Europe PubMed Central

PMC publication ID

14 September 2017

T-Y Liu

2

1 reference

Europe PubMed Central

PMC publication ID

14 September 2017

S L Skala

3

1 reference

Europe PubMed Central

PMC publication ID

14 September 2017

M J Magers

4

1 reference

Europe PubMed Central

PMC publication ID

14 September 2017

A S McDaniel

5

1 reference

Europe PubMed Central

PMC publication ID

14 September 2017

D E Spratt

6

1 reference

Europe PubMed Central

PMC publication ID

14 September 2017

F Y Feng

7

1 reference

Europe PubMed Central

PMC publication ID

14 September 2017

J Siddiqui

8

1 reference

Europe PubMed Central

PMC publication ID

14 September 2017

X Cao

9

1 reference

Europe PubMed Central

PMC publication ID

14 September 2017

K L Fields

10

1 reference

Europe PubMed Central

PMC publication ID

14 September 2017

T M Morgan

11

1 reference

Europe PubMed Central

PMC publication ID

14 September 2017

G S Palapattu

12

1 reference

Europe PubMed Central

PMC publication ID

14 September 2017

A Z Weizer

13

1 reference

Europe PubMed Central

PMC publication ID

14 September 2017

A M Chinnaiyan

14

1 reference

Europe PubMed Central

PMC publication ID

14 September 2017

A Alva

15

1 reference

Europe PubMed Central

PMC publication ID

14 September 2017

J S Montgomery

16

1 reference

Europe PubMed Central

PMC publication ID

14 September 2017

S A Tomlins

17

1 reference

Europe PubMed Central

PMC publication ID

14 September 2017

H Jiang

18

1 reference

Europe PubMed Central

PMC publication ID

14 September 2017

R Mehra

19

1 reference

Europe PubMed Central

PMC publication ID

14 September 2017

publication date

23 May 2016

1 reference

Europe PubMed Central

PMC publication ID

14 September 2017

Annals of Oncology

1 reference

Europe PubMed Central

PMC publication ID

14 September 2017

27

1 reference

Europe PubMed Central

PMC publication ID

14 September 2017

9

1 reference

Europe PubMed Central

PMC publication ID

14 September 2017

1706-1712

1 reference

Europe PubMed Central

PMC publication ID

14 September 2017

UV-Associated Mutations Underlie the Etiology of MCV-Negative Merkel Cell Carcinomas

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4999561

14 September 2017

Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4999561

14 September 2017

Association of Polymerase e-Mutated and Microsatellite-Instable Endometrial Cancers With Neoantigen Load, Number of Tumor-Infiltrating Lymphocytes, and Expression of PD-1 and PD-L1

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4999561

14 September 2017

Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4999561

14 September 2017

PD-1 Blockade in Tumors with Mismatch-Repair Deficiency

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4999561

14 September 2017

Pembrolizumab versus Ipilimumab in Advanced Melanoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4999561

14 September 2017

A Systematic Review of Immunotherapy in Urologic Cancer: Evolving Roles for Targeting of CTLA-4, PD-1/PD-L1, and HLA-G.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4999561

14 September 2017

Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4999561

14 September 2017

EAU guidelines on penile cancer: 2014 update.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4999561

14 September 2017

Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4999561

14 September 2017

Nivolumab in previously untreated melanoma without BRAF mutation

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4999561

14 September 2017

PD-L1 marks a subset of melanomas with a shorter overall survival and distinct genetic and morphological characteristics

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4999561

14 September 2017

Nivolumab plus ipilimumab in advanced melanoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4999561

14 September 2017

Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4999561

14 September 2017

Safety, activity, and immune correlates of anti-PD-1 antibody in cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4999561

14 September 2017

PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4999561

14 September 2017

The B7-H1 (PD-L1) T lymphocyte-inhibitory molecule is expressed in breast cancer patients with infiltrating ductal carcinoma: correlation with important high-risk prognostic factors.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4999561

14 September 2017

Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4999561

14 September 2017

Enhanced expression of PD L1 in cervical intraepithelial neoplasia and cervical cancers

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4999561

14 September 2017

Genomic Profiling of Penile Squamous Cell Carcinoma Reveals New Opportunities for Targeted Therapy.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4999561

25 September 2017

Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4999561

25 September 2017

Tumor B7-H1 and B7-H3 expression in squamous cell carcinoma of the lung.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4999561

20 August 2018

Incidence trends in primary malignant penile cancer.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4999561

20 August 2018

Expression of PDL1 (B7-H1) Before and After Neoadjuvant Chemotherapy in Urothelial Carcinoma.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW216

21 January 2018

PD-1-Expressing Tumor-Infiltrating T Cells Are a Favorable Prognostic Biomarker in HPV-Associated Head and Neck Cancer

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW216

21 January 2018

Releasing the Brakes on Cancer Immunotherapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4999561

4 November 2018

Checkpoint parley

1 reference

https://pubmed.ncbi.nlm.nih.gov/27217541

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

PDL1: The Illusion of an Ideal Biomarker

1 reference

https://pubmed.ncbi.nlm.nih.gov/27217541

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1093/ANNONC/MDW216

1 reference

Europe PubMed Central

PMC publication ID

14 September 2017

PMC publication ID

1 reference

Europe PubMed Central

PMC publication ID

14 September 2017

PubMed publication ID

1 reference

Europe PubMed Central

PMC publication ID

14 September 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q39741247&oldid=2089248444"